Saturday 17 October 2026
Export NVCR’s income statement to Excel — free account
NovoCure Limited
NVCR Healthcare Medical Devices
NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.
14.07
0.34
−2.36%
Follow NVCR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.51 | 1.84 | 2.20 | 2.25 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
216.13 | (92.05) | (80.06) | 70.28 | |
P/B ratio |
5.20 | 3.76 | 4.23 | 4.24 | |
Price to Tangible BV |
5.20 | 3.76 | 4.23 | 4.24 | |
EV/Sales |
2.15 | 1.54 | 1.80 | 0.94 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(533.92) | (38.59) | (24.04) | (17.53) | |
EV/FCF |
(59.09) | (21.58) | (15.58) | (9.27) | |
Quick Ratio |
2.70 | 2.70 | 2.71 | 1.50 | |
Current Ratio |
2.89 | 2.90 | 2.90 | 1.55 | |
Net Debt/EBITDA |
28.77 | 3.14 | 6.57 | 21.71 | |
Debt/Assets |
24.63% | 29.82% | 24.25% | 14.30% | |
Debt/Equity |
0.58 | 0.71 | 0.57 | 0.57 | |
Asset Turnover |
0.69 | 0.66 | 0.64 | 0.50 | |
Operating CF/Net income |
(0.52) | 0.19 | 0.73 | (0.55) | |
Capex/Depreciation |
(4.03) | (3.42) | (10.37) | 2.06 | |
Interest Coverage |
(5.59) | (36.68) | (72.00) | 6.00 | |
Research and Development Expense of Revenue |
28.02% | 33.52% | 34.93% | 32.31% | |
Selling, General and Administrative Expense of Revenue |
55.34% | 82.85% | 64.06% | 62.48% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
9.27% | 36.20% | 11.37% | 17.54% | |
Graham Net Nets |
0.10 | 0.14 | 0.13 | 0.12 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.58%) | (14.04%) | (9.44%) | (12.46%) | |
Free Cash Flow Yield |
(1.45%) | (3.86%) | (5.25%) | (4.51%) | |
Revenue per Share |
1.58 | 1.52 | 1.56 | 1.49 | |
Operating CF per Share |
0.07 | (0.12) | (0.16) | 0.18 | |
Capex per Share |
(0.06) | (0.05) | (0.04) | (0.05) | |
Free Cash Flow per Share |
0.01 | (0.16) | (0.21) | 0.13 | |
Cash per Share |
3.88 | 3.87 | 4.10 | 9.26 | |
Shareholders Equity per Share |
2.91 | 2.90 | 3.05 | 3.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.91 | 2.90 | 3.05 | 3.05 | |
Free Cash Flow |
1.22 | (18.67) | (22.90) | 14.92 | |
Working Capital |
417.81 | 414.09 | 423.50 | 423.85 | |
Capital Expenditures |
(6.92) | (5.15) | (4.90) | (5.65) | |
Net Current Asset Value |
181.42 | 174.45 | 182.87 | 179.99 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
137.44 | 132.48 | 128.70 | 108.61 | |
Average Payables |
117.20 | 111.16 | 113.66 | 105.12 | |
Average Inventory |
41.22 | 41.46 | 38.10 | 39.10 | |
Average Assets |
1,020.53 | 1,018.37 | 1,022.56 | 1,291.59 | |
Average Common Equity |
343.77 | 346.34 | 350.32 | 351.06 |
Columns are period end dates